logo

Vanda Pharmaceuticals (VNDA)



Trade VNDA now with
  Date
  Headline
2/13/2019 4:06:18 PM Vanda Pharmaceuticals Q4 EPS $0.19 Vs. Loss $0.04 Year Ago
12/20/2018 7:07:07 AM Vanda Pharma: FDA Accepts HETLIOZ SNDA For Review In Treatment Of Jet Lag Disorder
12/10/2018 7:05:37 AM Vanda Announces Positive Pivotal Study Results For HETLIOZ In Patients With Smith-Magenis Syndrome
12/3/2018 6:07:08 AM Vanda Says Tradipitant Met Primary Endpoint In VLY686-2301 Phase II Clinical Study
11/1/2018 9:41:47 AM Vanda Gets FDA Letter Regarding Corporate Webpage
8/13/2018 4:03:32 PM Vanda Pharmaceuticals Appoints Timothy Williams As SVP, General Counsel And Secretary
5/23/2018 8:07:09 AM Vanda Pharma Says HETLIOZ (tasimelteon) Effective In Treating Jet Lag During Transatlantic Travel
4/13/2018 12:24:30 PM Vanda Pharma Wins Appeal Case On Fanapt
4/6/2018 8:53:19 AM Jefferies Is Cutting VANDA PHARMACEUTICALS (VNDA) 2020 Estimate To 0.61 From 0.67
4/6/2018 8:53:03 AM Jefferies Is Lowering VANDA PHARMACEUTICALS (VNDA) 2019 Estimate To 0.83 From 0.92
4/6/2018 8:52:40 AM Jefferies Is Raising VANDA PHARMACEUTICALS (VNDA) 2018 Estimate To -0.83 From -0.92
3/14/2018 4:04:03 PM Vanda Pharmaceuticals Proposes Public Offering Of Common Stock